Digest Network Come funziona
Network
/
Società
Fo
Non verificato

Forlong Biotechnology

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

12 comunicati stampa

Guarda tutti i comunicati
04/08/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Forlong Biotechnology Announces Approval to Initiate Phase I Clinical Trial of FL115 (IL-15 Superagonist) Subcutaneous Injection in Australia
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
03/08/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Forlong Biotechnology Announces Successful Completion of GMP Pivotal Batch Production for FL115 (IL-15 Superagonist), Ready to Support Upcoming Phase III Clinical Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
27/05/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Forlong Announces Completion of Phase I Clinical Studies of FL115 Monotherapy (IV): Disease Control for 3 Heavily-pretreated Patients with Advanced Solid Tumors over 12 Months
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
19/05/2026
Oncologia
Associazioni/Professionisti
Salute
Finanza
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Forlong Raises Approximately 120 Million RMB in Series Pre-B Financing to Advance its IL-15 and IL-18 Pipeline
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
21/04/2026
Fiere
Analisi di mercato
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Forlong Biotechnology to Present Clinical Data from the First-in-human Study for FL115 (IL-15 Superagonist) in US Patients with Advanced Solid Tumors at 2026 ASCO Annual Meeting
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
15/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
17/03/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
07/01/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
30/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)
Fonte
Forlong Biotechnology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0